C
Carlos H. Barcenas
Researcher at University of Texas MD Anderson Cancer Center
Publications - 100
Citations - 2298
Carlos H. Barcenas is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 22, co-authored 85 publications receiving 1746 citations. Previous affiliations of Carlos H. Barcenas include Georgia Regents University.
Papers
More filters
Journal ArticleDOI
Birthplace, Years of Residence in the United States, and Obesity Among Mexican‐American Adults
Carlos H. Barcenas,Anna V. Wilkinson,Sara S. Strom,Yumei Cao,Katherine C. Saunders,Somdat Mahabir,María A. Hernández-Valero,Michele R. Forman,Michele R. Forman,Margaret R. Spitz,Melissa L. Bondy,Melissa L. Bondy +11 more
TL;DR: To evaluate the association between birthplace (Mexico or U.S.) and obesity in men and women and to analyze the relationship between duration of U.s. residency and prevalence of obesity in Mexican immigrants.
Journal ArticleDOI
Effects of nativity, age at migration, and acculturation on smoking among adult Houston residents of Mexican descent.
Anna V. Wilkinson,Margaret R. Spitz,Sara S. Strom,Alexander V. Prokhorov,Carlos H. Barcenas,Yumei Cao,Katherine C. Saunders,Melissa L. Bondy +7 more
TL;DR: Smoking interventions for people of Mexican descent should be tailored according to gender, nativity, and acculturation level and should target all ages, not just young people.
Journal ArticleDOI
Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery
Audree B Tadros,Wei T. Yang,Savitri Krishnamurthy,Gaiane M. Rauch,Benjamin Smith,Vicente Valero,Dalliah M. Black,Anthony Lucci,Abigail S. Caudle,Sarah M. DeSnyder,Mediget Teshome,Carlos H. Barcenas,Makesha V. Miggins,Beatriz E. Adrada,Tanya W. Moseley,Rosa F. Hwang,Kelly K. Hunt,Henry Mark Kuerer +17 more
TL;DR: The data provide the fundamental basis and rationale for management of the axilla in clinical trials of omission of cancer surgery when image-guided biopsy indicates a breast pCR.
Journal ArticleDOI
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.
Jennifer K. Litton,Marion E. Scoggins,Kenneth R. Hess,Beatriz E. Adrada,Rashmi Krishna Murthy,Senthil Damodaran,Sarah M. DeSnyder,Abenaa M. Brewster,Carlos H. Barcenas,Vicente Valero,Gary J. Whitman,Jill Schwartz-Gomez,Elizabeth A. Mittendorf,Alastair M. Thompson,Thorunn Helgason,Nuhad K. Ibrahim,Helen Piwnica-Worms,Stacy L. Moulder,Banu Arun +18 more
TL;DR: The substantive pathologic response of talazoparib alone for 6 months in patients with a known germline BRCA pathogenic variant (gBRCA-positive) and operable breast cancer supports the larger, ongoing neoadjuvant trial.
Journal ArticleDOI
Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal.
John T. Mullen,Miguel A. Rodriguez-Bigas,George J. Chang,Carlos H. Barcenas,Christopher H. Crane,John M. Skibber,Barry W. Feig +6 more
TL;DR: Patients who initially present with node-positive disease and patients who receive a radiation dose of less than 55 Gy as part of their initial chemoradiation therapy regimen have a worse prognosis after radical salvage surgery, but long-term survival can be achieved in the majority of patients.